跳至主要内容
临床试验/NCT02868385
NCT02868385已完成3 期

Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire

Leiden University Medical Center1 个研究点 分布在 1 个国家目标入组 167 人开始时间: 2018年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
167
试验地点
1
主要终点
Cure rate

研究概览

简要总结

An open label, randomized controlled trial of single vs. multiple treatments of praziquantel in intestinal African schistosomiasis in Côte d'Ivoire

This study aims to determine the efficacy of repeated (up to four times) praziquantel treatment against S. mansoni infection in school-age children from Côte d'Ivoire using the traditional Kato-Katz thick smear technique, but also with more accurate and non-invasive antigen- and DNA-detection methods.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
5 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Subject has a confirmed S. mansoni infection (positive POC-CCA test result and at least one positive out of triplicate Kato-Katz thick smears)
  • Subject is aged between 5 and 18 years and otherwise in good health
  • Subject has received no recent praziquantel treatment in the past month
  • Subject has provided oral assent and provided written informed consent signed by parents/legal guardian
  • Subject is able and willing to provide multiple stool and urine samples during study

排除标准

  • Known allergy to study medication (i.e. praziquantel and albendazole)
  • Pregnancy
  • Lactating

研究组 & 干预措施

Control group (A)

Active Comparator

1x praziquantel: Children assigned to group A receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive no further treatment until the final visit (week 8).

干预措施: 1x Praziquantel (Drug)

Intervention group (B)

Experimental

4x praziquantel: Children assigned to group B receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive three consecutive praziquantel treatments (40 mg/kg) in the following six weeks with 2 weeks intervals.

干预措施: 4x Praziquantel (Drug)

结局指标

主要结局

Cure rate

时间窗: 8 weeks

The difference in cure rate (percentage negative) between intervention and control arm by Kato-Katz technique

次要结局

  • Reduction rates(8 weeks)
  • Sensitivity and specificity(8 weeks)

研究者

发起方
Leiden University Medical Center
申办方类型
Other
责任方
Principal Investigator
主要研究者

Meta Roestenberg

MD PhD

Leiden University Medical Center

研究点 (1)

Loading locations...

相似试验